Trial Profile

A Phase I Randomized Double-blind Placebo-controlled Study With 2 Separate Cohorts to Assess the Safety, Tolerability and Pharmacokinetics of Verinurad and Allopurinol in Healthy Asian and Chinese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Allopurinol (Primary) ; Verinurad (Primary)
Indications Gout; Hyperuricaemia; Kidney disorders; Renal failure; Type 2 diabetes mellitus
Focus Adverse reactions
Sponsors AstraZeneca

10 May 2019 Status changed from active, no longer recruiting to completed.
16 Apr 2019 Planned End Date changed from 6 May 2019 to 1 May 2019.
16 Apr 2019 Planned primary completion date changed from 6 May 2019 to 1 May 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com